Deutsche Bank raised the firm’s price target on AbbVie (ABBV) to $180 from $175 and keeps a Hold rating on the shares. The company reported a quality Q3, but Emraclidine success looks already priced in, the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: